Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

23.04.25 15:50 Uhr

Werte in diesem Artikel

SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Shareholders Foundation
mail@shareholdersfoundation.com
(8585)779-1554 (PRNewsfoto/Shareholders Foundation, Inc.)

Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On February 11, 2025, a NASDAQ: NTLA investor filed a lawsuit against Intellia Therapeutics, Inc. over alleged violations of securities laws. The plaintiff alleged that between July 30, 2024 and January 08, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.

Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-for-investors-in-shares-of-intellia-therapeutics-inc-nasdaq-ntla-announced-by-the-shareholders-foundation-302435434.html

SOURCE Shareholders Foundation, Inc.

In eigener Sache

Übrigens: Intellia Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Intellia Therapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Intellia Therapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Intellia Therapeutics Inc

Wer­bung

Analysen zu Intellia Therapeutics Inc

DatumRatingAnalyst
02.11.2018Intellia Therapeutics NeutralWedbush Morgan Securities Inc.
15.05.2018Intellia Therapeutics BuyChardan Capital Markets
28.03.2017Intellia Therapeutics BuyChardan Capital Markets
31.05.2016Intellia Therapeutics OutperformWedbush Morgan Securities Inc.
DatumRatingAnalyst
15.05.2018Intellia Therapeutics BuyChardan Capital Markets
28.03.2017Intellia Therapeutics BuyChardan Capital Markets
31.05.2016Intellia Therapeutics OutperformWedbush Morgan Securities Inc.
DatumRatingAnalyst
02.11.2018Intellia Therapeutics NeutralWedbush Morgan Securities Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intellia Therapeutics Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen